De Visser; Peter Christian

Patent Applications and Registrations

Patent applications and USPTO patent grants for De Visser; Peter Christian.The latest application filed is for "oligonucleotide".

Company Profile

6.4.16

De Visser; Peter Christian - Leiden NL
De Visser; Peter Christian - Leiderdorp NL

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders Grant 11,345,915 - De Visser , et al. May 31, 2	2022-05-31
Oligonucleotide App 20220098586 - de Visser; Peter Christian ; et al.	2022-03-31
Substances for targeting various selected organs or tissues App 20210347825 - DE VISSER; Peter Christian ; et al.	2021-11-11
RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular Dystrophy App 20210108204 - de Visser; Peter Christian ; et al.	2021-04-15
RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy Grant 10,913,946 - de Visser , et al. February 9, 2	2021-02-09
Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Neuromuscular Disorders App 20200149043 - DE VISSER; Peter Christian ; et al.	2020-05-14
RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular Dystrophy App 20190194656 - de Visser; Peter Christian ; et al.	2019-06-27
RNA modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy Grant 10,179,912 - de Visser , et al. Ja	2019-01-15
RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular Dystrophy App 20180362973 - de Visser; Peter Christian ; et al.	2018-12-20
RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Neuromuscular Disorders App 20180066256 - de Visser; Peter Christian ; et al.	2018-03-08
Oligomers Having Bicyclic Scaffold Moeities App 20180028554 - Van DEUTEKOM; Judith Christina Theodora ; et al.	2018-02-01
RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders Grant 9,745,576 - de Visser , et al. August 29, 2	2017-08-29
Compounds For Treating, Delaying And/or Preventing A Human Genetic Disorder Such As Myotonic Dystrophy Type I (dmi) App 20170029820 - Aguilera Diez; Maria Begona ; et al.	2017-02-02
RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular Dystrophy App 20170029818 - de Visser; Peter Christian ; et al.	2017-02-02
RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Neuromuscular Disorders App 20150148404 - de Visser; Peter Christian ; et al.	2015-05-28
RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular Dystrophy App 20150045413 - De Visser; Peter Christian ; et al.	2015-02-12
Compounds For Treating, Delaying And/or Preventing A Human Genetic Disorder Such As Myotonic Dystrophy Type I (dmi) App 20140045763 - Aguilera Diez; Maria Begona ; et al.	2014-02-13
Sulfurization Agent And Its Use App 20110015384 - De Visser; Peter Christian ; et al.	2011-01-20
Antibiotic Composition App 20090318403 - De Visser; Peter Christian ; et al.	2009-12-24
Antibiotic drosocin derivatives App 20090312521 - Van Hooft; Petrus Albertus Venantia ; et al.	2009-12-17

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.